Results 311 to 320 of about 306,104 (338)
Some of the next articles are maybe not open access.
Adoptive Immunotherapy of Advanced Melanoma
Current Treatment Options in Oncology, 2012Adoptive cell therapy (ACT) has emerged as an effective therapy for patients with metastatic melanoma. Since the first introduction of the protocol in 1988 [1], major improvements have been achieved with response rates of 40%-72% among patients who were resistant to previous treatment lines.
Ronnie Shapira-Frommer +2 more
openaire +3 more sources
Costimulatory approaches to adoptive immunotherapy
Current Opinion in Oncology, 1998Costimulation is critical for induction of full T-cell effector function, and thus represents an attractive immunotherapeutic approach for the treatment of cancer. This review examines these approaches, including ex vivo T-cell expansion, systemic "delivery" of constimulation, tumors transduced or transfected with costimulatory ligands, and vaccine ...
Carl H. June +2 more
openaire +3 more sources
Adoptive immunotherapy for herpesviruses
2007Herpesvirus infections rarely cause significant problems in the immunocompetent human host. However, in the immunosuppressed, for example, recipients of hematopoietic stem cell transplants (HSCT) (Rooney et al., 1998), solid organ transplants (SOT), or human immunodeficiency virus (HIV)-infected individuals, viral infections/reactivations are common ...
Catherine M. Bollard +3 more
openaire +2 more sources
Technological advances in adoptive immunotherapy
Drugs of Today, 2005Adoptive immunotherapy is an attractive and elegant strategy for treating a variety of life-threatening diseases. Several approaches have been developed to generate antigen-specific CD4+ and CD8+ T cells for adoptive T-cell therapy in cancer and infectious diseases.
Christine Krueger +2 more
openaire +3 more sources
Review: Cardiopulmonary Toxicity of Adoptive Immunotherapy
The American Journal of the Medical Sciences, 1988Adoptive immunotherapy, the administration of interleukin-2 (IL-2) and interleukin-2 activated cells, leads to tumor regression in some patients with advanced cancer. Although this new therapeutic modality offers hope for the future, at present, a multitude of toxicities limit the total dose and duration of therapy.
Alpha A. Fowler +5 more
openaire +2 more sources
Adoptive Immunotherapy of Ovarian Carcinoma
Gynecologic Oncology, 2002SCOPUS: le.j ; info:eu-repo/semantics ...
de Gramont, Aimery +5 more
openaire +2 more sources
NK cell adoptive immunotherapy
Blood, 2005Comment on Miller et al, page [3051][1] In this issue of Blood, Miller and colleagues present data on the administration of haploidentical NK cells to cancer patients. They identify a feasible and safe method for in vivo NK cell expansion and clinical efficacy.
openaire +4 more sources
An artificial solution for adoptive immunotherapy
Trends in Biotechnology, 2003Abstract Adoptive immunotherapy is a promising strategy in the battle against cancer and infectious diseases and the recently developed artificial antigen-presenting cell (aAPC) overcomes several obstacles for this therapy. The aAPC recapitulates the natural in vivo antigen-presenting cell (APC)–T cell interactions by coupling human leukocyte ...
openaire +3 more sources
Adoptive T‐cell transfer in cancer immunotherapy
Immunology & Cell Biology, 2006Adoptive T‐cell therapy has definite clinical benefit in relapsed leukaemia after allogeneic transplant and in Epstein–Barr virus‐associated post‐transplant lymphoproliferative disease. However, the majority of tumour targets are weakly immunogenic self‐antigens and success has been limited in part by inadequate persistence and expansion of transferred
Tey, Siok-Keen +2 more
openaire +4 more sources
Adoptive T cell immunotherapy for cytomegalovirus
Expert Opinion on Biological Therapy, 2009Cytomegalovirus (CMV) is a major opportunistic pathogen following allogeneic transplantation, reflecting the inability of depressed host immunity to contain viral replication. Current antiviral drugs are limited by toxicities and lack of efficacy in established CMV disease, making adoptive immunotherapeutic strategies aimed at hastening virus-specific ...
openaire +3 more sources